Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.

Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there ...

We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...

AbbVie's CEO hinted his company may be less willing to invest in psychiatry after a costly setback, while Lilly explained ...

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

World stocks are mixed follow Wall Street’s mostly positive performance ahead of key U.S. inflation data that could influence ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...